Our Work

Findings suggest that Basaglar was not less expensive for patients than Lantus. Empirical evaluation of biosimilar costs prior to automatic substitution is necessary.

Interactions with wearable devices, smartphones, and social media generate user data, which can reveal sensitive health information. Those data can be used to improve individual and community health, but also raise security and privacy concerns. Given potential benefits alongside substantial privacy risks, it is important to evaluate how consumers view organizations and entities that collect and re-use their personal digital health data. We surveyed US consumers to assess their confidence in sixteen public and private organizations to use their digital health data responsibly.

In this cross-sectional analysis of the top 1000 generics in Colorado’s all-payer claims database in 2019, 45 high-cost generics that had lower-cost therapeutic alternatives of same clinical value were identified. Overall, high-cost generics were 15.6 times more expensive than their therapeutic alternatives (median values); if the lower-cost alternatives had been used, total spending would have been reduced by 88.3%.